MolecuLight announces Health Canada Approval for the MolecuLight i:X, its first diagnostic medical imaging device for wound care.

News provided by

MolecuLight

20 Oct, 2015, 01:30 ET

TORONTO, Oct. 20, 2015 /PRNewswire/ - MolecuLight Inc. has been authorized to sell the MolecuLight i:X by Health Canada. The approval will allow the company to begin selling the product throughout Canada.  MolecuLight i:X is a novel, handheld fluorescence imaging device that:

  • Provides real-time visualization of bacteria in chronic wounds.
  • Integrates into hospital acute care workflows.
  • Allows clinicians to better analyze the bacterial condition of chronic wounds with no patient contact or contrast agents.

(Photo: http://photos.prnewswire.com/prnh/20151020/278744)

For the first time, clinicians will be able to visualize bacteria in chronic wounds, this is particularly important for patients in an immunocompromised condition where the signs and symptoms of high bacterial loads or infection are not present.  The MolecuLight i:X enables clinicians to quickly, safely, and easily visualize and precisely target clinically important bacteria in and around chronic wounds, in real-time at the bedside allowing them to initiate targeted and precise treatment plans. 

'Canadian clinicians will now have a powerful new tool for more objective assessment of wound bacterial status and better antimicrobial treatment decision making' says Dr Ralph DaCosta, Founder, CSO and Director of MolecuLight.

'This is a historic day for wound care, we will now be able to offer clinicians real-time diagnostic information about bacterial load at the bedside' says Craig Kennedy, CEO. 

The MolecuLight i:X has proven its effectiveness in clinical trials in over 180 patients.  Results have shown the MolecuLight i:X can improve sample quality, healing rates, screen for high levels of bacteria and detect wound subsurface heavy bacte­rial load as well as subclinical local infection in patients. The device will impact how clinicians treat wounds as well as improve patients' quality of life.

About MolecuLight Inc.

Founded in 2012, and based in Toronto, Canada, MolecuLight Inc. is a privately-owned medical imaging company delivering fluorescence image-guidance solutions that provide clinicians with new information about wound bacterial burden for better diagnostic and treatment decisions.  MolecuLight strives to serve the healthcare industry with world-class products and services while delivering value to all its customers, employees and shareholders. For more information, please visit www.moleculight.com.

SOURCE MolecuLight

Related Links

www.moleculight.com

Also from this source

Latest Clinical Evidence Presented at APWCA's Wound Week™ 2023 Illustrates the Significant and New Clinical Utility of the MolecuLight Point-of-Care Imaging Platform

Seasoned Healthcare Executive David Bassin Joins the MolecuLight Board of Directors

Explore

More news releases in similar topics

PRN Top Stories Newsletters

Sign up to get PRN’s top stories and curated news delivered to your inbox weekly!

Thank you for subscribing!

By signing up you agree to receive content from us.
Our newsletters contain tracking pixels to help us deliver unique content based on each subscriber's engagement and interests. For more information on how we will use your data to ensure we send you relevant content please visit our PRN Consumer Newsletter Privacy Notice. You can withdraw your consent at any time in the footer of every email you'll receive. Mit Ihrer Anmeldung erklären Sie sich damit einverstanden, Inhalte von uns zu erhalten.
Unsere Newsletter enthalten Zählpixel, die die Lieferung einzigartiger Inhalte in Bezug auf das Abonnement und die Interessen der einzelnen Abonnenten ermöglichen. Weitere Informationen über die Verwendung Ihrer Daten im Hinblick auf die Zusendung von relevanten Inhalten, finden Sie in unserer PRN Consumer Newsletter Privacy Notice. Ihre Zustimmung können Sie jederzeit in der Fußzeile jeder erhaltenen E-Mail widerrufen. En vous inscrivant à la newsletter, vous consentez à la réception de contenus de notre part.
Notre newsletter contient des pixels espions nous permettant la fourniture à chaque abonné, d’un contenu unique en lien avec ses souscriptions et intérêts. Pour de plus amples informations sur l’utilisation faite de vos données en vue de l’envoi des contenus concernés, nous vous invitons à consulter la politique de confidentialité disponible à partir du lien suivant PRN Consumer Newsletter Privacy Notice. Vous pouvez à tout moment revenir sur votre consentement par le biais des informations situées au bas de chaque e-mail reçu. Регистрирайки се, Вие се съгласявате да получавате информационно съдържание от нас. Нашите бюлетини съдържат проследяващи пиксели, които ни помагат да предоставяме уникално съдържание въз основа на ангажираността и интересите на всеки абонат. За повече информация относно начина, по който ще използваме Вашите данни, за да гарантираме, че Ви изпращаме подходящо съдържание, моля, направете справка с нашето Уведомление за поверителност на потребителския бюлетин на PRN. Можете да оттеглите съгласието си по всяко време в долния колонтитул на всеки от имейлите, които ще получите.